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PViewpoint
The Case for Routine Genotyping
in Dual-Antiplatelet Therapy
Samir B. Damani, MD, PHARMD, Eric J. Topol, MD
La Jolla, California
Over 1 million coronary stent procedures are performed annually in the U.S., with dual-antiplatelet therapy,
which includes the use of both aspirin and clopidogrel, being a cornerstone in the management of these pa-
tients after coronary intervention. Now, recent data have surfaced demonstrating altered active metabolite levels
of clopidogrel in patients harboring hepatic cytochrome gene variants. These variants, which have been validated
through genome-wide association as the dominant explanation for the marked heterogeneity of clopidogrel re-
sponse, are linked to a significant increase in the risk for bleeding, stent thrombosis, myocardial infarction, and
death. With viable alternatives to clopidogrel now available, including higher clopidogrel maintenance and load-
ing doses, prasugrel, and ticagrelor, clinicians can now effectively guide therapy in those with at-risk gene vari-
ants by simple genotyping. Such an individualized approach can potentially prevent tens of thousands of adverse
cardiovascular events in the over 30% of those with European ancestry and over 40% of those with Asian or Afri-
can ancestry who harbor these important clopidogrel gain-of-function and loss-of-function alleles. (J Am Coll
Cardiol 2010;56:109–11) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.029s
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mpproximately 25% of all outpatient prescription drugs
lled in the U.S. are taken by patients with genetic poly-
orphisms that affect these drugs’ absorption, metabolism,
r excretion (1). These gene variants affect both drug safety
nd efficacy, but clinicians have only rarely exploited this
nowledge to improve patient outcomes. Recently, multiple
arge cohort studies have incontrovertibly linked genetic
olymorphisms in the hepatic cytochrome 2C19 (CYP2C19)
ystem to an alteration in the metabolite levels of clopidogrel
2–6). Now, a recent genome-wide association study has
roven that common variants in the CYP2C19 gene locus
re the dominant explanation for the genomic variance in
lopidogrel antiplatelet response (5). The consequences of
hese variants include significantly increased risk for bleed-
ng, myocardial infarction, stent thrombosis, and death
3–6). Herein, we provide a rationale for individualizing
ntiplatelet therapy on the basis of this vital pharmacoge-
etic information.
YP2C19 Variants
n 2006, investigators documented a 25% reduction in
latelet responsiveness to clopidogrel in healthy volunteer
arriers of a reduced-function CYP2C19 allele (7). Several
andidate gene studies involving thousands of patients have
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010, accepted March 2, 2010.ince validated and extended these initial findings to pa-
ients on clopidogrel therapy for acute coronary syndromes
nd coronary artery disease (2–4). Most important, over
ne-third of Europeans and over 40% of patients of African
nd Asian ancestry harbor these common gain-of-function
nd loss-of-function variants (5,6). Furthermore, loss-of-
unction allele carriers have a striking 3-fold increase in the
isk of stent thrombosis, myocardial infarction, and cardio-
ascular death, while gain-of-function allele carriers have an
pproximate 2-fold increase in the risk of Thrombolysis In
yocardial Infarction major and minor bleeding (3–6).
Surprisingly, despite the robust nature of the data
utlined here, detractors have cited numerous “holes” in
he evidence base preventing widespread acceptance of
he results. First, they reference the variability in gene
osage impact seen in the Simon et al. (2) study, in which
nly those carrying multiple alleles of CYP2C19 gene
ariants experienced increases in cardiovascular events. Crit-
cs also attest to the presence of alternative genetic and
nvironmental factors, such as polymorphisms in drug
bsorption (ABCB1) (2), other variants in drug metabolism
2B6) (4) or the P2Y12 receptor, smoking, and obesity as
ignificant mediators of clopidogrel response.
While these are all valid concerns, these arguments do not
ully consider the enormous breadth of evidence implicating
YP2C19 gene variants as the root cause of adverse
ardiovascular events during clopidogrel treatment. To fur-
her reconcile and solidify all existing data on genetic
odifiers of clopidogrel response, Shuldiner et al. (5)
onducted a very timely genome-wide association study.
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Routine Genotyping in Antiplatelet Therapy July 6, 2010:109–11These investigators first mea-
sured platelet aggregation in a
healthy cohort at baseline and
within 1 h after the last dose of
clopidogrel on day 7. They then
assessed over 400,000 single-
nucleotide polymorphisms for
association to platelet activity.
ot surprisingly, the most significant single-nucleotide
olymorphisms (1.5  1013) clustered around chromo-
ome 10q24, which is in high linkage disequilibrium with
he previously established reduced-function CYP2C19*2
llele, the most common loss-of-function CYP2C19 gene
ariant. Importantly, these single-nucleotide polymor-
hisms did not associate with platelet aggregation at base-
ine, thereby confirming CYP2C19 as the major genetic
ediator of clopidogrel response. In the next stage, the
nvestigators examined the effect of the CYP2C19 variant in
atients undergoing percutaneous coronary intervention. At
-year follow-up, carriers of this variant had a dramatic
40% increase in stent thrombosis and cardiovascular death,
losely mirroring the 3-fold increase in risk for major
dverse events seen in previous studies (2–4).
ndividualized Options
or Dual-Antiplatelet Therapy
nvestigators have recently demonstrated an 8-fold reduc-
ion in stent thrombosis by administering additional clopi-
ogrel loading doses in patients with poor baseline response
8). In some instances, up to 2,400 mg was required to
btain an adequate antiplatelet effect. In addition, recent
ata have shown that strategies aimed at doubling the
lopidogrel maintenance dose in the period immediately
fter stenting can confer a significant clinical benefit (9).
urthermore, prasugrel, a newly approved thienopyridine
ith more rapid and greater inhibition of platelets, has now
lso emerged as a viable option to standard clopidogrel
herapy. A recent clinical trial that used prasugrel in patients
ith acute coronary syndromes found a 20% reduction in
schemic end points and a 50% reduction in the rate of
tent thrombosis compared with individuals randomized to
he clopidogrel arm (10). Unfortunately, also observed was a
ignificant increased risk for major bleeding. Accordingly, a
elective strategy of giving clopidogrel solely to patients
arboring reduced function alleles would most likely mag-
ify prasugrel’s efficacy and limit the proportion of patients
xposed to its heightened bleeding risk.
Despite all of the current options outlined here, the most
ommonly used alternative to clopidogrel in the near future
ill likely be ticagrelor. The first of a new class of orally
ctive nonthienopyridine agents, ticagrelor has a reversible
ntiplatelet effect and does not require hepatic activation
11,12). Furthermore, this agent confers a faster, more
onsistent antiplatelet effect compared with clopidogrel
Abbreviations
and Acronyms
CYP2C19  hepatic
cytochrome 2C19
PFT  platelet function
testing11,12). Most recently, ticagrelor demonstrated significant iuperiority to clopidogrel in preventing ischemic events and,
or the first time, a significant mortality benefit (13). With
.S. Food and Drug Administration approval of ticagrelor
ikely to be expedited because of its observed mortality
enefit and lack of excess bleeding, some experts may argue
or the across-the-board use of this agent over clopidogrel.
owever, such calls would be premature for several reasons.
irst, similar to prasugrel, the modest 1.9% absolute risk
eduction of ischemic events seen with ticagrelor therapy
as likely predominantly conferred by patients in the
lopidogrel arm of the study who harbored resistance alleles.
herefore, for this reason and because of the anticipated
eneric availability of clopidogrel in 2011, ticagrelor may be
etter suited for those who are genetically poor responders
r have failed clopidogrel therapy.
ur Pharmacogenetic Future
any experts will continue to call for results from random-
zed prospective trials before individualizing antiplatelet
herapy on the basis of CYP2C19 carrier status, despite the
verwhelming evidence presented here. This doggedness
epresents a false premise for a number of reasons and
enies current patients state-of-the-art care. Certainly,
arge-scale efforts prospectively validating systematic geno-
yping should be performed and will be a valuable addition
o the current compendium of existing data. However, with
tent thrombosis rates in carriers of CYP2C19 as high as
1% (3), mortality associated with such events close to 50%,
nd a near 2-fold increase in the risk of bleeding in
YP2C19*17 carriers, we cannot afford to wait years for
esults from these trials that to date have yet to be initiated.
n the interim, we should implement all potential interven-
ions to help prevent the catastrophic outcomes of stent
hrombosis and death in the tens of thousands of patients
urrently at risk. Consistent with this line of reasoning, the
.S. Food and Drug Administration has now appropriately
dded a boxed warning to the clopidogrel label emphasizing
his increased risk of adverse cardiovascular outcomes in
ndividuals harboring the poor metabolizer genotypes (14).
his notice also advocates, as we have outlined here,
mplementing strategies aimed at adjusting clopidogrel dos-
ng or the use of alternative antiplatelet agents in these
igh-risk individuals.
Further, it should be duly noted that there will be
ubstantial challenges in planning a comprehensive prospec-
ive trial aimed at validating any pharmacogenetic approach
o clopidogrel therapy. First, we will need to incorporate all
he various combinations and permutations of treatment
nd surveillance strategies, including a clopidogrel mainte-
ance dose of 75 mg versus 150 mg, standard versus repeat
00-mg clopidogrel loading doses, prasugrel 5 mg versus 10
g, ticagrelor, and the effects of other antiplatelet agents yet
o emerge. Additional strategies will also include point-of-
are platelet function testing (PFT) and the duration of
ncreased dosing of clopidogrel. Finally, it should also be
n
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July 6, 2010:109–11 Routine Genotyping in Antiplatelet Therapyoted that no current viable randomized design exists to
ully account for patient frailty, coronary anatomy, and left
entricular function with respect to bleeding risk and clinical
utcomes.
Critics of CYP2C19 genotyping will also suggest that
FT after percutaneous coronary intervention is a better
lternative for measuring both genetic and environmental
ediators of platelet response. However, data from a
ecently published study would indicate otherwise (15). In
his trial, investigators used 6 separate commonly used
ethods to assess baseline platelet function after appropri-
te clopidogrel loading in over 1,000 patients who received
oronary stents. At 1-year follow-up, only 3 of the 6 assays
ere prognostic for adverse cardiovascular events, with only
of the 6 assays being predictive for stent thrombosis.
urthermore, the predictive capacities of these tests were
odest compared with genotyping and, notably, did not
oretell a patient’s risk for bleeding (3–6,15). Other prob-
ems with PFT include results that are inconsistent and
ynamic when assessed at different times in the same
atient, lack of a standard definition of suboptimal platelet
esponse, and disagreement on the best method for mea-
uring platelet function (16). In contrast, CYP2C19 geno-
yping could be performed rapidly before percutaneous
oronary intervention, thereby identifying a subset of pa-
ients at high risk for bleeding or thrombotic events who
ould then be monitored with point-of-care PFT for ade-
uate clopidogrel response or potentially switched to an
lternative agent such as prasugrel or ticagrelor.
The use of genotyping, with or without PFT, represents the
rototype of individualized medicine for the future (17). The
lopidogrel story involves the second most highly prescribed
edicine in the U.S. and one of the most common medical
rocedures performed, in over 1.2 million patients each year
18). We believe that the evidence threshold supporting
ndividualized clopidogrel therapy has been clearly sur-
assed, leveraging new knowledge from pharmacogenomic
nd epidemiologic studies to select the right drug for the
ight patient. Translational medicine is not just a matter of
ringing science to the practice of medicine; it also requires
he appropriate timing and making the call that adequate
ata have accumulated to change the routine clinical care of
atients. Such is the case for genotyping with the use of
lopidogrel.
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